CMA vs. CQA: Understanding the Difference in Pharmaceutical Technology Transfer: Conflating input material attributes with output product characteristics is a quiet but persistent source of scale-up failure.
Building Once, Validating Forever: Why Scalable CQV Is the Future-Proof Strategy Life Sciences Manufacturers Can’t Ignore – Scalability is the difference between a validation program that becomes a growing liability and one that becomes a strategic asset as your operation expands.
Restricted Access Barrier Systems (RABS) have emerged as a cutting-edge technology to address challenges, providing a robust solution for aseptic processing in pharmaceutical and biotechnology industries. In this article, we will delve into what RABS technologies are and explore the steps involved in their successful implementation.
Validation by design thinking in the pharmaceutical industry, often referred to as “Validation 4.0”, is a shift in approach that adapts to the evolution of the industry.
Definition Validation Master Plan is an approved written plan of objectives and actions stating how and when a company will achieve compliance with the GMP requirements regarding validation. It is a document which defines the intentions and the methods that are related with validation of facilities, utilities, system, equipment, instruments, materials, analytical methods, It Systems, cleaning procedures